DERmbiont's MICROBIAL Therapeutics Platform

  • Dysbiosis is the root cause of skin disease

  • Whole genome sequencing and bioinformatics will reveal the functional implications of a dysbiosis

  • We are only starting with fungal infections; our platform spans across a myriad of skin diseases

LEAD indications

  • T. pedis interdigital

  • T. pedis moccasin

  • Onychomycosis 

Issues with Current Treatments

  • Low patient response rate around 30%

  • Undesirable side effects (oral antifungals)

  • Frequent recurrences and repetitive treatments

  • Ignore the role of the microbiome

DERMBIONT's APPROACH Advantages

  • Strong IP position

  • Capital and time efficient development plan